

Table S1. Changes in biochemical, clinical and functional markers in women with RA without responding to or loss of response to TNFaI therapy over time.

No Of Patients	Parameter	RA Patients With Primary Fail To Respond To TNFaI Therapy (n = 2)			
		Before TNFaI Therapy	After Starting TNFaI Therapy		
		T ₀	T ₁ (3 Months)	T ₂ (9 Months)	T ₃ (15 Months)
Patient 1	Age [years]	45			
	Disease duration [years]	15			
	SW, n	12	10	-	-
	TEN, n	14	28	-	-
	VAS, [0-100 mm]	80	80	-	-
	DAS28-ESR	6.36	7.40	-	-
	ESR [mm/h]	22	32	-	-
	CRP [mg/l]	4	3	-	-
	TNFaI therapy	ADA (Humira)			
Patient 2	Age [years]	32			
	Disease duration [years]	9			
	SW, n	9	5	-	-
	TEN, n	11	15	-	-
	VAS, [0-100 mm]	70	90	-	-
	DAS28-ESR	5.22	6.09	-	-
	ESR [mm/h]	9	18	-	-
	CRP [mg/l]	2	3	-	-
	TNFaI therapy	ADA (Humira)			
RA Patients With Secondary Loss Of Response To TNFaI Therapy (n = 3)					
Patient 3	Age [years]	62			
	Disease duration [years]	5			
	SW, n	10	3	11	-
	TEN, n	14	8	13	-
	VAS, [0-100 mm]	60	45	65	-
	DAS28-ESR	6.68	4.38	6.03	-
	ESR [mm/h]	59	11	22	-
	CRP [mg/l]	15	11	10	-
	TNFaI therapy	ETA (Enbrel)			
Patient 4	Age [years]	60			-
	Disease duration [years]	21			-
	SW, n	6	3	10	-
	TEN, n	9	7	10	-
	VAS, [0-100 mm]	90	50	50	-
	DAS28-ESR	6.47	3.92	5.96	-
	ESR [mm/h]	57	6	41	-
	CRP [mg/l]	30	2	48	-
	TNFaI therapy	ETA (Enbrel)			
Patient 5	Age [years]	52			-
	Disease duration [years]	19			-
	SW, n	10	1	8	-
	TEN, n	10	0	12	-
	VAS, [0-100 mm]	80	5	70	-
	DAS28-ESR	5.73	1.48	5.57	-
	ESR [mm/h]	16	5	14	-
	CRP [mg/l]	40	2	2	-
	TNFaI therapy	ADA (Humira)			

CRP, C-reactive protein; DAS28-ESR, 28 joint disease activity score based on erythrocyte sedimentation rate; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; SW, swollen joint count; TEN, tender joint count; TNFaI, tumor necrosis factor- α inhibitors; VAS, visual analogue scale.